Table 2.

Patient Summary

Patient	Age (years)	Sex	KPS	MGMT Methylation	Humoral Response		DTH Response		PFS (months)	OS (months)
					Before Vaccination	After Vaccination	Before Vaccination	After Vaccination
1	62	M	90	ME	N/A	N/A	—	—	6.7	16.2
2	49	M	80	N/A	N/A	N/A	—	—	6.4	18.0
3	51	M	100	N/A	N/A	N/A	—	—	9.9	21.0
4	48	M	100	U	—	+*	—	+	58.5†	58.5‡
5	52	M	100	ME	—	—	—	—	13.5	22.6
6	42	M	100	U	—	—	—	+	14.9	35.8
7	51	M	90	U	—	—	—	+	54.6†	54.6‡
8	33	M	100	N/A	—	—	—	—	53.7†	53.7‡
9	46	F	90	ME	—	—	—	—	15.4	34.9
10	29	M	90	N/A	—	—	—	N/A	6.4	11.2
11	64	M	90	U	N/A	N/A	—	—	12.0	21.6
12	64	M	80	U	—	+	—	—	27.6	44.1
13	54	F	90	N/A	—	—	—	—	17.6	26.0
14	63	M	80	ME	—	+	—	—	10.9	20.8
15	67	F	80	ME	—	+	—	—	6.5	13.4
16	53	F	100	ME	—	+	—	—	30.0	47.7
17	52	M	100	ME	—	+	—	—	5.4	47.4‡
18	64	F	90	U	—	—	—	—	16.4	23.1

Abbreviations: KPS, Karnofsky performance status; MGMT, methylguanine methyltransferase; DTH, delayed-type hypersensitivity; PFS, progression-free survival; OS, overall survival; M, male; ME, methylated; N/A, sample not available; U, unmethylated; F, female; (—), no response; (+), positive response.

^*Positive humoral response in CSF.

^†No progression.

^‡Alive.